Skip to main content

Candidemia clinical trials at UC Health
2 research studies open to new patients

  • A Study of Experimental Medicine CD101 For Candidemia and/or Invasive Candidiasis (fungal infections in the blood and/or organs)

    open to eligible people ages 18 years and up

    The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

    at UC Davis

  • A Study of the Effectiveness and Safety Study of Experimental APX001 for Candidemia (fungal infection in the blood)

    open to eligible people ages 18-80

    This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in non-neutropenic patients 18 to 80 years of age (inclusive). Suspicion of antifungal-resistant candidemia is sufficient (documented resistance is not required for enrollment). The Study Drug Treatment Period of APX001 will be a maximum of 14 days. After completion of 14 days study drug therapy, if further antifungal treatment is indicated to complete treatment of candidemia in accordance with standard practice guidelines, fluconazole (unless susceptibility results warrant alternative antifungal therapy) may commence for up to a further 7 days. There will be a Follow up Period of 4 weeks (+4 days) after EOT. The total duration of participation in the study is up to approximately 7.5 weeks. This study will be conducted at approximately 20 sites in the United States and globally.

    at UC Davis

Last updated: